AMRA-MEDICAL
2.5.2024 15:36:33 CEST | Business Wire | Press release
AMRA Medical - a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms - collaborated on a study driven by University of Texas Southwestern and University Hospital Cleveland to publish new data revealing the effect of liraglutide treatment on muscle composition in adults with obesity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502719692/en/
Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher
The analysis included 128 diabetes-free adults with obesity who received a lifestyle intervention in addition to being randomized to either a liraglutide (n = 73) or a placebo (n = 55) treatment group. Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the primary objective of assessing change in thigh muscle fat infiltration due to treatment intervention over a 40-week period. Participants were also assessed for the exploratory outcome of adverse muscle composition, defined as high muscle fat infiltration and low muscle volume z-score.
Among the 128 participants, median muscle fat infiltration at baseline was 7.8%. The study found that liraglutide significantly reduced muscle fat infiltration when compared to placebo. The mean percent change in muscle fat infiltration for those randomized to liraglutide was -2.87% from baseline, and 0.05% in the placebo arm (absolute change: -0.23% vs. 0.01%). Additionally, a weight-invariant assessment of muscle volume was performed using AMRA’s muscle volume z-score did not show a significant reduction comparing liraglutide to placebo (mean treatment difference adjusted for baseline muscle volume z-score was -0.08 standard deviations). The study also uncovered that the proportion of participants with adverse muscle composition dropped from 11.0% to 8.2% over follow-up in the liraglutide arm, while no change in the placebo arm was observed.
While the contribution of muscle fat infiltration improvement to the cardiometabolic benefits of liraglutide requires further investigation, the above findings come at a critical time given the global rise of obesity incidence and its comorbidities posing more of a threat to patients than ever before. As the treatment paradigm begins to shift from solely lifestyle changes to one that includes pharmacological intervention (namely the popular GLP-1 agonists such as liraglutide) and drug development in obesity ramps up, it is paramount that these drugs are accurately assessed for their impact on muscle composition to ensure that the weight loss they help to achieve does not result in adverse effects on muscle health.
Through their gold-standard MRI-based body composition analysis technology, AMRA is committed to pioneering the creation of normative datasets explaining the effect of GLP-1s and incretin-based treatments on muscle composition to help the obesity field gain further insight as to how these drugs work in this relatively new indication. Recently, AMRA presented related findings at the 59th European Association for the Study of Diabetes Annual Meeting, where it was shown that another popular GLP-1, tirzepatide, achieved significant weight loss without any adverse effects on muscle composition. You can view the presentation here.
Learn more about AMRA Medical and how the use of MRI-based body composition analysis is advancing disease research in metabolic diseases including obesity, and beyond.
About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502719692/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TetraMem Announces 22nm Multi-Level RRAM Analog In-Memory Computing SoC Milestone16.5.2026 10:43:00 CEST | Press release
TetraMem Inc., a Silicon Valley–based semiconductor company developing analog in-memory computing (IMC) solutions, today announced the successful tape-out, manufacturing, and initial silicon validation of its MLX200 platform, a 22nm multi-level RRAM-based analog IMC system-on-chip (SoC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260516556464/en/ Photograph of the MLX200 chip with a five-cent coin for size reference The achievement marks a significant step toward the commercialization of analog computing architectures based on emerging non-volatile memory technologies, addressing the growing challenges of data movement, power consumption, and thermal constraints in modern AI systems. As AI workloads continue to scale, system performance is increasingly constrained by the cost of moving data between memory and compute units. Analog in-memory computing offers a fundamentally different approach by performing computation dir
STARTEEPO Invest Announces 5% Stake in Xerox Holdings Corporation15.5.2026 18:15:00 CEST | Press release
STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has acquired a significant ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515594020/en/ As of the date of this release, STARTEEPO and its affiliates beneficially owns 6.6 million shares of Xerox (excluding options), representing approximately 5.05% of the Company’s outstanding common stock. STARTEEPO has filed a Schedule 13D with the U.S. Securities and Exchange Commission (the “SEC”) providing additional details regarding its investment. Investment Perspective STARTEEPO believes that Xerox represents an interesting investment opportunity supported by a combination of balance sheet initiatives, ongoing operational improvements, and its position within a changing and consolidating industry. In STARTEEPO’s view, the Company
NTT DATA Announces Intent to Acquire WinWire to Scale Enterprise AI Adoption and Accelerate Industry Transformation with Microsoft15.5.2026 16:00:00 CEST | Press release
Accelerates AI‑driven transformation through expanded agentic AI and data engineering capabilities that underpin NTT DATA’s AI strategy Adds 1,000 Azure engineers and AI specialists to scale cloud and AI delivery capabilities Advances NTT DATA’s North America leadership position, scaling industry aligned AI led innovation across its cloud services and Microsoft Business Unit Builds on NTT DATA’s position as the fastest-growing Microsoft GSI partner, accelerating co-innovation in enterprise AI NTT DATA, a global leader in AI, digital business and IT services, today announced it has signed a definitive agreement to acquire WinWire,an award-winning Microsoft partner specializing in Agentic AI, AI on Azure, data engineering and cloud-native development as foundational capabilities for enterprise AI. The acquisition strengthens NTT DATA’s position as a trusted partner to help organizations move beyond experimentation to operationalize AI at scale. The acquisition further advances NTT DATA’s
NTT DATA Announces Intent to Acquire WinWire to Scale Enterprise AI Adoption and Accelerate Industry Transformation with Microsoft15.5.2026 16:00:00 CEST | Press release
Accelerates AI‑driven transformation through expanded agentic AI and data engineering capabilities that underpin NTT DATA’s AI strategy Adds 1,000 Azure engineers and AI specialists to scale cloud and AI delivery capabilities Advances NTT DATA’s North America leadership position, scaling industry aligned AI led innovation across its cloud services and Microsoft Business Unit Builds on NTT DATA’s position as the fastest-growing Microsoft GSI partner, accelerating co-innovation in enterprise AI NTT DATA, a global leader in AI, digital business and IT services, today announced it has signed a definitive agreement to acquire WinWire,an award-winning Microsoft partner specializing in Agentic AI, AI on Azure, data engineering and cloud-native development as foundational capabilities for enterprise AI. The acquisition strengthens NTT DATA’s position as a trusted partner to help organizations move beyond experimentation to operationalize AI at scale. The acquisition further advances NTT DATA’s
Experian Expands Agent Trust Partner Ecosystem with Akamai to Advance Trusted AI Driven Commerce15.5.2026 15:00:00 CEST | Press release
Collaboration strengthens secure, scalable agentic commerce and supports emerging Know Your Agent standards Experian today announced that Akamai Technologies has joined its growing partner ecosystem, designed to further advance secure, trusted AI driven commerce through the Experian Agent Trust™ framework, alongside partner Skyfire supporting emerging payment innovation. As AI agents begin to search, decide, and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer directly initiated by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust is designed to address this challenge by establishing identity, accountability, and trust in agent driven interactions. “Trust, security, and performance must scale alongside the growing role of AI agents in digital commerce,” said Kathleen Peters,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom